TLR7 (Toll-like receptor 7) variants and mutations
TLR7 (also known as Toll-like receptor 7) is a human protein-coding gene encoding a toll-like receptor 7 protein. It detects single-stranded viral RNA in endosomes and drives type I interferon and inflammatory responses, particularly in plasmacytoid dendritic cells and B cells. Loss-of-function variants can predispose to severe viral infection, whereas gain-of-function variants cause immune dysregulation and autoimmunity. This analysis covers 1,228 TLR7 variants and mutations. Of these, 94% have computational variant effect predictions. Disease context includes systemic lupus erythematosus, rheumatoid arthritis, and immunodeficiency 74, COVID-19-related, X-linked. Example TLR7 variants include V2M, V2L, and V2E.
Variant analysis overview
- Gene: TLR7
- Protein: Toll-like receptor 7
- UniProt accession: Q9NYK1
- Organism: Homo sapiens
- Variants analyzed: 1228
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 704 unspecified-consequence records; 232 missense variants; 1 splice-region variants; 262 synonymous variants; 6 stop-gained variants; 16 frameshift variants; 5 in-frame deletions; 1 in-frame insertions; 1 substitution
- Prediction scores: 1,150 variants have prediction scores (94% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: systemic lupus erythematosus, rheumatoid arthritis, immunodeficiency 74, COVID-19-related, X-linked, actinic keratosis, systemic lupus erythematosus 17, basal cell carcinoma, malaria, keratosis, anogenital human papillomavirus infection, cutaneous lupus erythematosus, COVID-19, neurodegenerative disease.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 14 post-translational modification sites.
- Structural context: 119 variants have structural context.
- PTM context: 18 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TLR7 variants
Examples include V2M, V2L, V2E, V2V, F3L, P4L, P4T, M5L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- V2M (p.Val2Met), Ensembl rs755364962, REVEL 0.10, MetaLR 0.07
- V2L (p.Val2Leu), gnomAD X-12885512-G-T, REVEL 0.07, MetaLR 0.08
- V2E (p.Val2Glu), gnomAD X-12885513-T-A, REVEL 0.05, MetaLR 0.06
- V2V (p.Val2Val), gnomAD X-12885514-G-A, CADD 0.72
- F3L (p.Phe3Leu), Ensembl rs2042907038, MetaLR 0.07, MetaSVM -1.02
- P4L (p.Pro4Leu), gnomAD rs1258108007, REVEL 0.05, MetaLR 0.08
- P4T (p.Pro4Thr), gnomAD X-12885518-C-A, REVEL 0.04, MetaLR 0.08
- M5L (p.Met5Leu), TOPMed rs1480048433, gnomAD rs1480048433, REVEL 0.03, MetaLR 0.05
- M5V (p.Met5Val), TOPMed rs1480048433, gnomAD rs1480048433, REVEL 0.01, MetaLR 0.06
- M5K (p.Met5Lys), gnomAD X-12885522-T-A, REVEL 0.07, MetaLR 0.08
- M5I (p.Met5Ile), gnomAD X-12885523-G-A, REVEL 0.07, MetaLR 0.06
- W6* (p.Trp6Ter), TOPMed rs1174969183, gnomAD rs1174969183, CADD 34.00
- W6G (p.Trp6Gly), gnomAD X-12885524-T-G, REVEL 0.09, MetaLR 0.07
- T7P (p.Thr7Pro), Ensembl rs781486181, REVEL 0.17, MetaLR 0.09, Uncertain significance, not provided
- T7K (p.Thr7Lys), gnomAD X-12885528-C-A, REVEL 0.05, MetaLR 0.07
- L8P (p.Leu8Pro), ESP rs371046642, TOPMed rs371046642, gnomAD rs371046642, REVEL 0.36, MetaLR 0.16, Uncertain significance, not provided
- L8L (p.Leu8Leu), gnomAD X-12885530-C-T, CADD 0.21
- L8M (p.Leu8Met), gnomAD X-12885530-C-A, REVEL 0.15, MetaLR 0.11
- K9N (p.Lys9Asn), rs1191062173, TOPMed rs1191062173, gnomAD rs1191062173, REVEL 0.06, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- K9T (p.Lys9Thr), gnomAD X-12885534-A-C, REVEL 0.06, MetaLR 0.08
- R10G (p.Arg10Gly), TOPMed rs1490750885, REVEL 0.07, MetaLR 0.08
- R10K (p.Arg10Lys), rs2518437016, ClinGen CA412403696, ClinVar RCV003024288, REVEL 0.02, MetaLR 0.07, Uncertain significance, not provided
- R10* (p.Arg10Ter), gnomAD X-12885536-A-T, CADD 33.00
- R10R (p.Arg10Arg), gnomAD X-12885538-A-G, CADD 6.28
- Q11* (p.Gln11Ter), ExAC rs756933603, gnomAD rs756933603, CADD 31.00
- Q11K (p.Gln11Lys), ExAC rs756933603, gnomAD rs756933603, REVEL 0.11, MetaLR 0.07
- Q11L (p.Gln11Leu), rs179008, ClinGen CA10349891, ClinVar RCV002846219, ClinVar RCV003491156, REVEL 0.04, MetaLR 0.00, Benign, not provided; not specified
- Q11P (p.Gln11Pro), 1000Genomes rs179008, ESP rs179008, ExAC rs179008, TOPMed rs179008, MetaLR 0.06, MetaSVM -1.02, Benign
- L13L (p.Leu13Leu), rs201163901, gnomAD X-12885547-T-C, CADD 4.61
- I14N (p.Ile14Asn), gnomAD X-12885549-T-A, REVEL 0.24, MetaLR 0.16
- I14T (p.Ile14Thr), gnomAD X-12885549-T-C, REVEL 0.19, MetaLR 0.15
- L15I (p.Leu15Ile), Ensembl rs952821919, REVEL 0.02, MetaLR 0.08
- F16S (p.Phe16Ser), Ensembl rs1602438494, MetaLR 0.05, MetaSVM -1.03
- N17K (p.Asn17Lys), gnomAD X-12885559-C-A, REVEL 0.04, MetaLR 0.06
- I19M (p.Ile19Met), ExAC rs745786993, TOPMed rs745786993, gnomAD rs745786993, MetaLR 0.10, MetaSVM -1.01
- I19T (p.Ile19Thr), gnomAD X-12885564-T-C, REVEL 0.14, MetaLR 0.12
- I19I (p.Ile19Ile), gnomAD X-12885565-C-A, CADD 5.46
- L20V (p.Leu20Val), gnomAD X-12885566-C-G, REVEL 0.02, MetaLR 0.09
- L20L (p.Leu20Leu), rs1437151164, gnomAD X-12885568-A-G, CADD 2.75
- S22Y (p.Ser22Tyr), NCI-TCGA Cosmic COSV6612, Variant assessed as somatic; moderate impact.
- K23R (p.Lys23Arg), TOPMed rs1489798746, REVEL 0.05, MetaLR 0.05
- K23K (p.Lys23Lys), gnomAD X-12885577-A-G, CADD 7.32
- L24I (p.Leu24Ile), gnomAD X-12885578-C-A, REVEL 0.02, MetaLR 0.08
- L24P (p.Leu24Pro), rs776066956, gnomAD X-12885578-CT-C, CADD 22.00
- L25P (p.Leu25Pro), gnomAD rs1354435927, REVEL 0.09, MetaLR 0.10
- L25V (p.Leu25Val), TOPMed rs202195261, MetaLR 0.10, MetaSVM -1.00
- L25F (p.Leu25Phe), gnomAD X-12885581-C-T, REVEL 0.02, MetaLR 0.09
- L25L (p.Leu25Leu), rs147937650, gnomAD X-12885583-T-C, CADD 8.16
- G26G (p.Gly26Gly), gnomAD X-12885586-G-A, CADD 6.90
- A27D (p.Ala27Asp), NCI-TCGA TCGA novel, MetaLR 0.12, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- A27S (p.Ala27Ser), rs1299955214, NCI-TCGA Cosmic COSV1010, gnomAD rs1299955214, REVEL 0.06, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- A27P (p.Ala27Pro), gnomAD X-12885587-G-C, REVEL 0.13, MetaLR 0.14
- R28G (p.Arg28Gly), rs2147245261, ClinGen CA412403934, ClinVar RCV002248405, UniProt VAR 087534, AlphaMissense 0.10, MetaLR 0.07, Pathogenic, in SLEB17
- R28I (p.Arg28Ile), rs2518437067, ClinGen CA412403942, ClinVar RCV003713394, Uncertain significance, not provided
- R28T (p.Arg28Thr), gnomAD X-12885591-G-C, REVEL 0.05, MetaLR 0.07
- R28R (p.Arg28Arg), rs776821332, gnomAD X-12885592-A-G, CADD 10.40
- F30L (p.Phe30Leu), TOPMed rs1298719672, gnomAD rs1298719672, REVEL 0.12, MetaLR 0.11, Uncertain significance, not specified
- F30F (p.Phe30Phe), gnomAD X-12885598-T-C, CADD 10.50
- P31S (p.Pro31Ser), rs1218801965, NCI-TCGA Cosmic COSV6612, gnomAD rs1218801965, AlphaMissense 0.27, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- P31P (p.Pro31Pro), gnomAD X-12885601-T-C, CADD 9.52
- T33L (p.Thr33Leu), NCI-TCGA TCGA novel, MetaLR 0.15, MetaSVM -0.88, Variant assessed as somatic; high impact.
- T33T (p.Thr33Thr), rs748200247, gnomAD X-12885607-T-G, CADD 6.61
- P35S (p.Pro35Ser), NCI-TCGA Cosmic COSV6612, MetaLR 0.25, MetaSVM -0.57, Variant assessed as somatic; moderate impact.
- C36C (p.Cys36Cys), rs200308543, gnomAD X-12885616-T-C, CADD 8.22
- V38I (p.Val38Ile), gnomAD rs1236184253, REVEL 0.18, MetaLR 0.15
- V38V (p.Val38Val), rs1370746032, gnomAD X-12885622-C-T, CADD 1.31
- L40P (p.Leu40Pro), ESP rs373668842, ExAC rs373668842, TOPMed rs373668842, MetaLR 0.10, MetaSVM -1.01
- D41E (p.Asp41Glu), rs757348701, ClinGen CA326797071, ClinVar RCV002913452, Ensembl rs757348701, REVEL 0.01, MetaLR 0.05, Uncertain significance, not provided
- D41H (p.Asp41His), ExAC rs763384185, gnomAD rs763384185
- D41Y (p.Asp41Tyr), NCI-TCGA TCGA novel, MetaLR 0.12, MetaSVM -0.98, Variant assessed as somatic; moderate impact.
- V42A (p.Val42Ala), TOPMed rs1602438547, MetaLR 0.02, MetaSVM -1.07
- V42D (p.Val42Asp), gnomAD X-12885633-T-A, REVEL 0.05, MetaLR 0.04
- P43S (p.Pro43Ser), gnomAD X-12885635-C-T, REVEL 0.05, MetaLR 0.00
- K44R (p.Lys44Arg), rs1306830975, ClinGen CA412404133, ClinVar RCV003730641, ClinVar RCV004676266, REVEL 0.11, MetaLR 0.00, Uncertain significance, not specified; not provided
- K44Q (p.Lys44Gln), gnomAD X-12885638-A-C, REVEL 0.05, MetaLR 0.00
- N45K (p.Asn45Lys), gnomAD X-12885643-C-A, REVEL 0.03, MetaLR 0.01
- N45N (p.Asn45Asn), gnomAD X-12885643-C-T, CADD 1.77
- H46R (p.His46Arg), ExAC rs766652668, gnomAD rs766652668, REVEL 0.13, MetaLR 0.01
- H46H (p.His46His), rs201767808, gnomAD X-12885646-T-C, CADD 0.21
- V47A (p.Val47Ala), gnomAD X-12885648-T-C, REVEL 0.36, MetaLR 0.30
- V47G (p.Val47Gly), gnomAD X-12885648-T-G, REVEL 0.41, MetaLR 0.30
- I48T (p.Ile48Thr), gnomAD X-12885651-T-C, REVEL 0.03, MetaLR 0.04
- I48I (p.Ile48Ile), rs1015731658, gnomAD X-12885652-C-T, CADD 0.09
- V49A (p.Val49Ala), TOPMed rs1347564910, MetaLR 0.15, MetaSVM -0.97
- V49M (p.Val49Met), ESP rs141847327, ExAC rs141847327, TOPMed rs141847327, gnomAD rs141847327, REVEL 0.42, MetaLR 0.42, Uncertain significance, not provided
- V49V (p.Val49Val), rs2042907867, gnomAD X-12885655-G-A, CADD 4.40
- D50N (p.Asp50Asn), Ensembl rs2042907884
- D50Y (p.Asp50Tyr), NCI-TCGA Cosmic COSV6612, MetaLR 0.29, MetaSVM -0.50, Variant assessed as somatic; moderate impact.
- T52A (p.Thr52Ala), TOPMed rs2095286604, REVEL 0.17, MetaLR 0.11, Uncertain significance, not specified; not provided
- T52I (p.Thr52Ile), NCI-TCGA TCGA novel, gnomAD rs2042907902, REVEL 0.19, MetaLR 0.14, Variant assessed as somatic; moderate impact.
- T52T (p.Thr52Thr), rs1250732476, gnomAD X-12885664-A-G, CADD 5.13
- D53Y (p.Asp53Tyr), NCI-TCGA Cosmic COSV1010, MetaLR 0.13, MetaSVM -0.95, Variant assessed as somatic; moderate impact.
- D53D (p.Asp53Asp), rs767969308, gnomAD X-12885667-C-T, CADD 4.66
- H55Q (p.His55Gln), ExAC rs752222864, gnomAD rs752222864, REVEL 0.02, MetaLR 0.01
- H55R (p.His55Arg), TOPMed rs961142291, REVEL 0.04, MetaLR 0.00
- L56L (p.Leu56Leu), rs2042907992, gnomAD X-12885674-T-C, CADD 3.65
- P60H (p.Pro60His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P60S (p.Pro60Ser), NCI-TCGA Cosmic COSV6612, MetaLR 0.62, MetaSVM 0.49, Variant assessed as somatic; moderate impact.
- G61E (p.Gly61Glu), ExAC rs755519400, gnomAD rs755519400, REVEL 0.04, MetaLR 0.04
- G61R (p.Gly61Arg), TOPMed rs1404650069, gnomAD rs1404650069, REVEL 0.07, MetaLR 0.04
- G62C (p.Gly62Cys), TOPMed rs958741253, REVEL 0.34, AlphaMissense 0.31
- G62S (p.Gly62Ser), rs958741253, ClinGen CA412404253, ClinVar RCV002829558, AlphaMissense 0.31, MetaLR 0.36, Uncertain significance, not provided
- G62G (p.Gly62Gly), gnomAD X-12885694-T-G, CADD 2.31
- I63T (p.Ile63Thr), gnomAD X-12885696-T-C, REVEL 0.40, MetaLR 0.27
- P64L (p.Pro64Leu), NCI-TCGA TCGA novel, MetaLR 0.35, MetaSVM -0.32, Variant assessed as somatic; moderate impact.
- P64P (p.Pro64Pro), gnomAD X-12885700-C-T, CADD 2.48
- T65A (p.Thr65Ala), rs2042908064, ClinGen CA412404273, ClinVar RCV002755954, TOPMed rs2042908064, REVEL 0.02, MetaLR 0.04, Uncertain significance, not provided
- T65M (p.Thr65Met), rs200329031, NCI-TCGA Cosmic COSV6612, TOPMed rs200329031, gnomAD rs200329031, REVEL 0.07, MetaLR 0.13, Variant assessed as somatic; moderate impact.
- T65T (p.Thr65Thr), rs201345374, gnomAD X-12885703-G-A, CADD 2.60
- T67A (p.Thr67Ala), 1000Genomes rs752095862, ExAC rs752095862, TOPMed rs752095862, gnomAD rs752095862, REVEL 0.09, MetaLR 0.01
- T67T (p.Thr67Thr), rs1355149790, gnomAD X-12885709-C-A, CADD 1.69
- T68M (p.Thr68Met), TOPMed rs1411084015, gnomAD rs1411084015, REVEL 0.45, MetaLR 0.43
- T68P (p.Thr68Pro), gnomAD X-12885710-A-C, REVEL 0.54, MetaLR 0.38
- T68T (p.Thr68Thr), rs199530355, gnomAD X-12885712-G-C, CADD 2.01
- N69S (p.Asn69Ser), gnomAD X-12885714-A-G, REVEL 0.12, MetaLR 0.11
- L70F (p.Leu70Phe), NCI-TCGA Cosmic COSV6612, MetaLR 0.07, MetaSVM -1.07, Variant assessed as somatic; moderate impact.
- T71I (p.Thr71Ile), Ensembl rs2042908219, MetaLR 0.25, MetaSVM -0.64
- T71T (p.Thr71Thr), rs200989312, gnomAD X-12885721-C-A, CADD 2.89
- T73P (p.Thr73Pro), gnomAD X-12885725-A-C, REVEL 0.41, MetaLR 0.32
- I74M (p.Ile74Met), rs2518437179, ClinGen CA412404333, ClinVar RCV003668812, REVEL 0.28, MetaLR 0.17, Uncertain significance, not provided
- N75N (p.Asn75Asn), gnomAD X-12885733-C-T, CADD 7.36
- H76R (p.His76Arg), gnomAD X-12885735-A-G, REVEL 0.09, MetaLR 0.08
- I80V (p.Ile80Val), Ensembl rs2042908274, MetaLR 0.01, MetaSVM -0.96
- P82L (p.Pro82Leu), rs2518437192, ClinGen CA412404389, ClinVar RCV004121507, REVEL 0.08, MetaLR 0.01, Uncertain significance, not specified
- A83E (p.Ala83Glu), NCI-TCGA Cosmic COSV6612, MetaLR 0.00, MetaSVM -0.90, Variant assessed as somatic; moderate impact.
- A83V (p.Ala83Val), rs143823510, ClinGen CA10349909, NCI-TCGA Cosmic COSV6612, ClinVar RCV002948283, REVEL 0.03, MetaLR 0.01, Uncertain significance, not provided
- A83A (p.Ala83Ala), rs148180952, gnomAD X-12885757-G-A, CADD 7.24
- S84S (p.Ser84Ser), rs758443488, gnomAD X-12885760-C-T, CADD 8.52
- F85L (p.Phe85Leu), gnomAD X-12885761-T-C, REVEL 0.40, MetaLR 0.02
- H86L (p.His86Leu), ExAC rs200654867, gnomAD rs200654867, REVEL 0.03, MetaLR 0.01
- R87G (p.Arg87Gly), gnomAD X-12885767-A-G, REVEL 0.08, MetaLR 0.00
- L88L (p.Leu88Leu), gnomAD X-12885770-C-T, CADD 7.80
- D89G (p.Asp89Gly), rs2518437221, ClinGen CA412404432, ClinVar RCV004323211, Uncertain significance, not specified
- D89N (p.Asp89Asn), gnomAD X-12885773-G-A, REVEL 0.10, MetaLR 0.01
- H90N (p.His90Asn), Ensembl rs2042908417
- H90Y (p.His90Tyr), rs2042908417, ClinGen CA412404438, ClinVar RCV003689655, AlphaMissense 0.06, MetaLR 0.00, Uncertain significance, not provided
- H90H (p.His90His), gnomAD X-12885778-T-C, CADD 2.83
- L91M (p.Leu91Met), NCI-TCGA Cosmic COSV6612, MetaLR 0.19, MetaSVM -0.48, Variant assessed as somatic; moderate impact.
- V92I (p.Val92Ile), rs201304033, ClinGen CA10349913, ClinVar RCV003738341, ClinVar RCV003900914, REVEL 0.07, MetaLR 0.01, Conflicting interpretations, not specified; not provided
- V92L (p.Val92Leu), ESP rs201304033, ExAC rs201304033, TOPMed rs201304033, gnomAD rs201304033, MetaLR 0.01, MetaSVM -0.96, Benign
- V92V (p.Val92Val), gnomAD X-12885784-A-C, CADD 4.43
- E93Q (p.Glu93Gln), gnomAD X-12885785-G-C, REVEL 0.30, MetaLR 0.03
- I94T (p.Ile94Thr), gnomAD X-12885789-T-C, REVEL 0.34, MetaLR 0.04
- I94I (p.Ile94Ile), rs769698470, gnomAD X-12885790-C-T, CADD 1.61
- I94M (p.Ile94Met), gnomAD X-12885790-C-G, REVEL 0.20, MetaLR 0.02
- D95N (p.Asp95Asn), rs200138463, NCI-TCGA Cosmic COSV1010, Ensembl rs200138463, REVEL 0.28, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- F96L (p.Phe96Leu), NCI-TCGA Cosmic COSV6612, MetaLR 0.00, MetaSVM -0.88, Variant assessed as somatic; moderate impact.
- R97K (p.Arg97Lys), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- R97T (p.Arg97Thr), gnomAD X-12885798-G-C, REVEL 0.40, MetaLR 0.01
- N99K (p.Asn99Lys), gnomAD X-12885805-C-G, REVEL 0.40, MetaLR 0.10
- N99N (p.Asn99Asn), gnomAD X-12885805-C-T, CADD 8.17
- C100R (p.Cys100Arg), gnomAD X-12885806-T-C, REVEL 0.64, MetaLR 0.01
- C100Y (p.Cys100Tyr), gnomAD X-12885807-G-A, REVEL 0.56, MetaLR 0.03
- C100C (p.Cys100Cys), rs2042908509, gnomAD X-12885808-T-C, CADD 7.65
- V101I (p.Val101Ile), gnomAD X-12885809-G-A, REVEL 0.06, MetaLR 0.00
- P102H (p.Pro102His), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6612, Variant assessed as somatic; moderate impact.
- P102L (p.Pro102Leu), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6612, MetaLR 0.02, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- P104S (p.Pro104Ser), TOPMed rs1476909613, gnomAD rs1476909613, REVEL 0.08, MetaLR 0.05
- P104T (p.Pro104Thr), TOPMed rs1476909613, gnomAD rs1476909613, REVEL 0.07, MetaLR 0.07
- P104A (p.Pro104Ala), gnomAD X-12885818-C-G, REVEL 0.06, MetaLR 0.06
- L105L (p.Leu105Leu), rs773554481, gnomAD X-12885821-C-T, CADD 0.30
- G106E (p.Gly106Glu), gnomAD X-12885825-G-A, REVEL 0.36, MetaLR 0.12
- G106G (p.Gly106Gly), rs749461862, gnomAD X-12885826-G-A, CADD 1.13
- S107L (p.Ser107Leu), gnomAD X-12885828-C-T, REVEL 0.10, MetaLR 0.07
- S107S (p.Ser107Ser), gnomAD X-12885829-A-G, CADD 0.18
- N109T (p.Asn109Thr), TOPMed rs2042908636, MetaLR 0.06, MetaSVM -1.04
- N109N (p.Asn109Asn), rs771364175, gnomAD X-12885835-C-T, CADD 0.91
- N110S (p.Asn110Ser), NCI-TCGA Cosmic COSV1010, REVEL 0.14, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- M111T (p.Met111Thr), rs2518437288, ClinGen CA412404585, ClinVar RCV003569422, REVEL 0.12, MetaLR 0.08, Uncertain significance, not provided
- C112G (p.Cys112Gly), gnomAD X-12885842-T-G, REVEL 0.42, MetaLR 0.09
- I113F (p.Ile113Phe), rs774725136, ClinGen CA10349918, ClinVar RCV003728240, ExAC rs774725136, REVEL 0.05, MetaLR 0.09, Uncertain significance, not provided
- I113L (p.Ile113Leu), ExAC rs774725136, gnomAD rs774725136, REVEL 0.03, MetaLR 0.03, Uncertain significance
- I113V (p.Ile113Val), ExAC rs774725136, gnomAD rs774725136, REVEL 0.03, MetaLR 0.05, Uncertain significance
- K114N (p.Lys114Asn), NCI-TCGA TCGA novel, MetaLR 0.05, MetaSVM -0.97, Variant assessed as somatic; moderate impact.
- L116L (p.Leu116Leu), rs1484816249, gnomAD X-12885854-C-T, CADD 4.60
- Q117K (p.Gln117Lys), rs201467088, ClinGen CA10349920, ClinVar RCV003720793, ClinVar RCV004266372, REVEL 0.01, MetaLR 0.00, Uncertain significance, not provided; not specified
- I118V (p.Ile118Val), rs1569109178, ClinGen CA412404633, ClinVar RCV003574365, Ensembl rs1569109178, AlphaMissense 0.10, MetaLR 0.01, Uncertain significance, not provided
- R121R (p.Arg121Arg), rs140749805, gnomAD X-12885869-A-C, CADD 2.29
- S122R (p.Ser122Arg), TOPMed rs1325766304, MetaLR 0.03, MetaSVM -1.17
- G125V (p.Gly125Val), gnomAD rs1461048823, REVEL 0.07, MetaLR 0.01
Public TLR7 analysis runs
- TLR7 analysis run — TLR7 (1,228 variants) — completed 2026-08-19